Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by BeerYaakov Mental Health Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
BeerYaakov Mental Health Center
ClinicalTrials.gov Identifier:
NCT00708396
First received: July 1, 2008
Last updated: January 26, 2009
Last verified: January 2009

July 1, 2008
January 26, 2009
July 2008
July 2010   (final data collection date for primary outcome measure)
  • 1. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Symptom Checklist [ Time Frame: on a weekly basis during the whole 13 weeks period ] [ Designated as safety issue: No ]
  • 2. Positive and negative symptoms scale ( PANSS) [ Time Frame: on a weekly basis during the whole 13 weeks period ] [ Designated as safety issue: No ]
  • 3. The Clinical Global Impression scales (CGI) consist of two sub-scales: The Severity of illness (CGI-S) and the Global improvement (CGI-I). [ Time Frame: on a weekly basis during the whole 13 weeks period ] [ Designated as safety issue: No ]
  • 4. Blood lipids and blood glucose prior to escitalopram up-titration over 20mg/d and at last visit [ Time Frame: on a weekly basis during the whole 13 weeks period ] [ Designated as safety issue: No ]
  • 5. EKG and physical examination will be performed at baseline 6. AE checklist at every visit 7. Recent and concomitant medications at every visit [ Time Frame: on a weekly basis during the whole 13 weeks period ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00708396 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study
Not Provided

The purpose of the study is to evaluate tolerability and efficacy of escitalopram (Cipralex) treatment in doses beyond 20mg (20-40 mg/d) in patients with OCD and schizophrenia, non responsive or partially responsive to recommended doses (evaluation according to Y-BOCS).

An open label, prospective study. The study will include 20 patients recruited from the inpatient wards and from the outpatient clinic who have a DSM-IV diagnosis of schizophrenia or schizoaffective disorder and OCD.

Before entering the study all patients will be interviewed by 2 senior board certified psychiatrists in order to confirm the diagnosis of schizophrenia or schizoaffective disorder and OCD according to DSM-IV criteria.

After confirming the diagnosis of schizophrenia/schizoaffective disorder and OCD each patient will be evaluated by PANSS, Y-BOCS and GCI-S scales. Those patients who score above 12 points on the Y-BOCS will be eligible for the study.

Rating scales (PANSS, Y-BOCS, CGI-S, CGI-I) will be completed on a weekly basis during the whole 13 weeks period. In addition patients will be asked to report medication side effects and will also be clinically evaluated for side effects by the physician. Special attention will be paid to worsening of psychosis or OC symptoms. All patients whose mental status will deteriorate or those who cannot tolerate the drug will be dropped-out and intent to treat analysis will be made.

Not Provided
Interventional
Phase 4
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • OCD
  • Schizophrenia
Drug: Escitalopram
First week; 10mg/d of Escitalopram Weeks 2-5; 20mg/d of Escitalopram After 4 weeks of 20mg treatment (2-5 weeks of the study) - if partial/no response according to YBOCS score and clinical judgment, the dose will be increased up to 30mg for 4 weeks (weeks 6-9) and in case of partial/ non response the dose will be increased up to 40 mg until the completion of the study (weeks 10-13).
Experimental: Patients
Patients which diagnosed as OCD and schizophrenia
Intervention: Drug: Escitalopram
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
July 2010
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All patients will be men and women over 18 years of age who meet DSM-IV criteria for schizophrenia/ schizoaffective disorder and OCD.
  • Previous to entering the study all patients should be stabilized on antipsychotic medication for at least 3 months.
  • Patients should score above 12 points on Yale Brown Obsessive Compulsive Scale (Y-BOCS) (Cut off point of Y-BOCS total score > or =7 is the common practice in similar studies) (Kayahan et al 2005).

Exclusion Criteria:

  • All patients who are under antidepressant treatment (including SSRIs and clomipramine).
  • In patients who were on clomipramine or SSRI in the past are included, at least 2 weeks must have been elapsed since stopping the medication.
  • In case the patient has received an antidepressant which is not an SSRI or clomipramine, there will be a washout period of one week before entering the study.
  • If the patient received a MAO-inhibitors there will be a washout period of at least 2 weeks except for fluoxetine for which a washout period of 5 weeks is required due to its long half-life.
  • Known contraindication for the use of citalopram or escitalopram.
  • Abnormal ECG findings at baseline
  • Unable to understand and give informed consent.
Both
18 Years and older
No
Contact: Rafael Octavio Stryjer, MD 972-8-9258404 stryjer@gmail.com
Contact: Igor Timinsky, MD 972-8-9258404 Igor.Timinsky@beerness.health.gov.il
Israel
 
NCT00708396
Escitalopram -199CTIL
Yes
BeerYaakov Mental Health Center
BeerYaakov Mental Health Center
Not Provided
Principal Investigator: Rafael Octavio Stryjer, MD Beer-Yaacov MHC
BeerYaakov Mental Health Center
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP